RPE65 Gene Therapy Effective for Retinal Dystrophy

Article

AAV2/5-OPTIRPE65 showed improvements in vision-guided mobility, retinal sensitivity, and foveal-driven visual function for patients with RPE65-associated retinal dystrophy.

Michel Michaelides, BSc, MB BS

Michel Michaelides, BSc, MB BS

Subretinal administration of the gene therapy AAV2/5-OPTIRPE65 showed improvements in vision-guided mobility, retinal sensitivity, and foveal-driven visual function for patients with RPE65-associated retinal dystrophy, according to findings from a phase 1/2 study presented at the 2019 American Academy of Ophthalmology Annual Meeting.

In the early-stage study, there was a significant change in the ability to complete a maze across lux levels when using the treated eye versus the fellow eye for navigation. At a mean 24 weeks from baseline following treatment with AAV2/5-OPTIRPE65 across all doses, patients navigated the maze 77.41 seconds quicker using the study eye versus the fellow eye (P = .0017). Moreover, there were significantly fewer errors in the treated group and the agent was well-tolerated.

"In terms of efficacy, we saw statistically significant improvements in vision-guided mobility," said Michel Michaelides, BSc, MB BS, from the UCL Institute of Ophthalmology & Moorfields Eye Hospital. "Our data suggest that our optimized vector improved functional vision, retinal function, and central vision."

Deficiency in the RPE65 gene causes a lack of rod function and leads to slowly progressive degeneration, with outer retina degeneration typically seen by the third generation of life. The AAV2/5-OPTIRPE65 gene therapy vector is an intron and codon-optimized transgene with an AAV5 capsid designed to deliver a normal copy of the RPE65 gene. In RPE65-deficient mice, the therapy was able to restore function at significantly lower doses than first-generation agents.

The phase 1/2 study included patients aged 3 or older with confirmed balletic RPE65-associated retinal dystrophy in an initial dose escalation cohort. All patients had structural evidence of photoreceptor preservation on SD-OCT. Three doses of AAV2/5-OPTIRPE65 were explored in the study: 1 x 1011, 3 x 1011, and 1 x 1012, all up to 1 ml. Treatment was administered as a subretinal injection into 4 subretinal blebs to target the entire central retina and involving foveal detachment. Overall, 8 mazes were utilized to measure navigation, and different mazes were used from baseline to 24 weeks for each patient.

Across the phase 1/2 portions of the study, 15 patients were enrolled. Of these patients, 9 were young adults with a mean age of 19.9 years and 6 were children at a mean age of 9.3 years. Most patients were treated in the United Kingdom at the Moorfields Eye Hospital, with 2 pediatric patients treated in the United States at the Michigan Kellogg Eye Center. The 1 x 1011 dose was selected for a pediatric expansion cohort enrolling 6 patients.

Across all patients treated with the dose selected for further study (1 x 1011; n = 9), there was a 107.73 seconds improvement in the time needed to navigate the maze for the treated-eye versus the fellow eye at week-24 (P = .0039). In pediatric patients treated with the 1 x 1011 dose (n = 6), there was a 131.52 seconds improvement across all lux levels with AAV2/5-OPTIRPE65 treatment (P = .031).

There was a significant improvement in retinal sensitivity in eyes treated with the gene therapy. Across all doses and treated patients at 24 weeks (N = 14), there was a 3.0922 dB-sr increase in volume of total hill of vision for patients treated with the gene therapy versus the fellow eye. In patients treated with the 1 x 1011 dose, there was a 9.39 dB-sr improvement in the treated versus untreated eyes. In pediatric patients treated at the 1 x 1011 dose (n = 5), there was a 12.58 dB-sr improvement in mean volume of total hill of vision with AAV2/5-OPTIRPE65.

At 6 months, there was an improvement in foveal-driven visual function with AAV2/5-OPTIRPE65 at 1 x 1011. The BCVA improved by a median of 4.3 letters in all patients treated at the 1 x 1011 dose and by 5.3 letters in children specifically (P = .031). There were also improvements in contrast sensitivity (P = .016), reading speed (P = .078), and central visual field (P = .008).

The most common adverse event was inflammation, which was seen primarily at the intermediate and high doses in 3 out of 6 patients (50%). For most patients, steroid cover was extended to treat this event. "Inflammation may have mitigated efficacy in these cohorts," Michaelides noted. "The therapy was generally well-tolerated. Importantly, there was no retinal thinning observed, including following foveal detachment."

Based on prior findings from studies exploring AAV2/5-OPTIRPE65, the FDA has granted the therapy a rare pediatric disease designation for the treatment of inherited retinal dystrophy due to biallelic RPE65 disease-causing variants. The therapy is also being explored for patients with Leber congenital amaurosis.

Michaelides M, Kumaran N, Georgiadis T, et al. Six-Month Results of a Phase 1/2 Study of AAV2/5-0PTIRPE65 Gene Therapy for the Treatment of RPE65-Associated Retinal Dystrophy. Presented at: 2019 AAO Annual Meeting, San Francisco, CA, October 12-15, 2019.

Related Videos
Arshad Khanani, MD
Alfonso Sabater, MD, PhD
Shankar Musunuri, PhD
Ula V. Jurkunas, MD
Alfonso Sabater, MD, PhD, on Bringing Gene Therapy to Ophthalmology
Shankar Musunuri, PhD
Ula V. Jurkunas, MD, on Developing CALEC Transplant for Limbal Stem Cell Deficiency
Alfonso Sabater, MD, PhD, on Treating Ocular DEB With B-VEC
David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMD
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
© 2024 MJH Life Sciences

All rights reserved.